|
Abstract:
|
Dose-finding studies in rare diseases are faced with unique challenges including low patient numbers, limited understanding of the dose-exposure-response relationship, variability around the endpoints and a lack of established Minimum Clinically Important Difference. In addition, patient exposure to placebo is often not feasible. To describe the disease progression for different dose groups, we introduce a longitudinal model for the change from baseline for a clinical endpoint. We build a nonlinear mixed effects model using the techniques which have become popular over the past two decades in the design and analysis of population pharmacokinetic/pharmacodynamics studies. To evaluate operating characteristics of the proposed design, we derive the Fisher information matrix and validate analytical results via simulations. Alternative considerations, such as trend analysis, will be discussed as well.
|
